The intraperitoneal injection of NsiRNA resulted in a significant STAT3 mRNA and protein reduction in the tumor samples in opposition to naked STAT3 siRNA treatment, as indicated in a xenograft lung cancer model. This evidence concerns the gene STAT3 and lung carcinoma.